<p>总部位于马萨诸塞州的 <strong>Moderna Inc.</strong> (NASDAQ: MRNA] 最近几周正迎来新的动力，2026 年的股票表现势头强劲。</p>
<p>这家公司因其 mRNA 疫苗在 COVID-19 疫情期间而声名鹊起，自 2021 年创下历史高点以来，股价已大幅下跌 91.87%。然而，随着多个有利因素的出现，公司似乎再次迎来了转机。</p>
<h2>Moderna 的动能激增</h2>
<p><strong>Benzinga 的 Edge 股票排名</strong> 中的动能得分是衡量股票强度的指标，基于其价格波动和多个时间框架内的波动性计算，并与其他股票进行百分位排名。</p>
<p>Moderna 的动能得分在短短一周内从 22.5 飙升至 74.61，反映出投资者情绪的急剧好转。该股票目前较 2025 年 11 月的低点上涨了 76%，并且在过去一个月内股价上涨了 31.7%，仅在过去一周又增加了 14.8%。</p>
<p>这一走势源于 Moderna 的 2025 年全年展望好于预期，预计收入为 19 亿美元，比第三季度财报电话会议中提供的中位数高出约 1 亿美元。公司还改善了成本预期，将 GAAP 运营费用预测下调了约 2 亿美元。</p>
<p>此外，公司将预计的年末现金余额提高至 81 亿美元，进一步激发了投资者对这只被压制股票的乐观情绪。</p>
<p>周四，Moderna 的股价下跌 3.01%，收于 39.36 美元，隔夜上涨 0.66%。该股票在 <strong>Benzinga 的 Edge 股票排名</strong> 中动能得分较高，短期、中期和长期的价格趋势均表现良好。</p>
<p></p>
<p><em>图片来源：pcruciatti / Shutterstock</em></p>

MRNA

<p>位于马萨诸塞州的 Moderna Inc.（纳斯达克代码：MRNA）正在经历复苏，其动量评分在短短一周内从 22.5 上升至 74.61。该股票自 2025 年 11 月的低点上涨了 76%，这得益于对 2025 年 19 亿美元的收入展望超出预期，以及运营费用减少 2 亿美元。尽管最近下跌了 3.01%，但股价在一夜之间上涨了 0.66%，反映出投资者的乐观情绪回暖</p>

<p>Massachusetts-based <strong>Moderna Inc.</strong> (NASDAQ: MRNA) is seeing fresh momentum in recent weeks, with the stock off to a flying start in 2026.</p>
<div class="lb-trans"><p>总部位于马萨诸塞州的 <strong>Moderna Inc.</strong> (NASDAQ: MRNA] 最近几周正迎来新的动力，2026 年的股票表现势头强劲。</p>
</div><p>The company that rose to prominence during the COVID-19 pandemic, for its mRNA vaccines, has witnessed a steep 91.87% decline since its all-time high in 2021. Things, however, are starting to look up once again for the company, with several tailwinds aligning in its favor.</p>
<div class="lb-trans"><p>这家公司因其 mRNA 疫苗在 COVID-19 疫情期间而声名鹊起，自 2021 年创下历史高点以来，股价已大幅下跌 91.87%。然而，随着多个有利因素的出现，公司似乎再次迎来了转机。</p>
</div><h2>Moderna’s Momentum Spikes</h2>
<div class="lb-trans"><h2>Moderna 的动能激增</h2>
</div><p>The Momentum score in <strong>Benzinga’s Edge Stock Rankings</strong> is a sign of strength in a stock, calculated based on its price movements and volatility across multiple time frames, before being ranked as a percentile against others.</p>
<div class="lb-trans"><p><strong>Benzinga 的 Edge 股票排名</strong> 中的动能得分是衡量股票强度的指标，基于其价格波动和多个时间框架内的波动性计算，并与其他股票进行百分位排名。</p>
</div><p>Moderna's Momentum score has surged from 22.5 to 74.61 in just one week, reflecting a sharp turnaround in investor sentiment. The stock is now up 76% from its November 2025 lows, and the rally hasn't cooled off, with shares climbing 31.7% in the past month and adding another 14.8% over the past week alone.</p>
<div class="lb-trans"><p>Moderna 的动能得分在短短一周内从 22.5 飙升至 74.61，反映出投资者情绪的急剧好转。该股票目前较 2025 年 11 月的低点上涨了 76%，并且在过去一个月内股价上涨了 31.7%，仅在过去一周又增加了 14.8%。</p>
</div><p>The move follows Moderna's better-than-expected full-year 2025 outlook, with revenue now projected at $1.9 billion, about $100 million above the midpoint provided during the third-quarter earnings call. The company also improved its cost picture, lowering its GAAP operating expense forecast by roughly $200 million for the year.</p>
<div class="lb-trans"><p>这一走势源于 Moderna 的 2025 年全年展望好于预期，预计收入为 19 亿美元，比第三季度财报电话会议中提供的中位数高出约 1 亿美元。公司还改善了成本预期，将 GAAP 运营费用预测下调了约 2 亿美元。</p>
</div><p>It also increased its projected year-end cash balance to $8.1 billion, fueling significant investor optimism around the beaten-down stock.</p>
<div class="lb-trans"><p>此外，公司将预计的年末现金余额提高至 81 亿美元，进一步激发了投资者对这只被压制股票的乐观情绪。</p>
</div><p>Shares of Moderna were down 3.01% on Thursday, closing at $39.36, and are up 0.66% overnight. The stock scores high on Momentum in <strong>Benzinga’s Edge Stock Rankings</strong>, with a favorable price trend in the short, medium and long terms.</p>
<div class="lb-trans"><p>周四，Moderna 的股价下跌 3.01%，收于 39.36 美元，隔夜上涨 0.66%。该股票在 <strong>Benzinga 的 Edge 股票排名</strong> 中动能得分较高，短期、中期和长期的价格趋势均表现良好。</p>
</div><p></p>
<div class="lb-trans"><p></p>
</div><p><em>Photo courtesy: pcruciatti / Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源：pcruciatti / Shutterstock</em></p>
</div>

这家在 COVID 时代备受青睐的生物科技公司因强劲的第四季度指引再次大幅上涨：动量得分激增